Can You Take Evenity (Romosozumab) with Hormonal Contraceptives?

Why This Combination Comes Up Clinically

Romosozumab (brand name Evenity) received FDA approval in 2019 for postmenopausal women with osteoporosis at high fracture risk [1]. The prescribing population skews older. Still, premenopausal patients prescribed romosozumab exist. Glucocorticoid-induced osteoporosis affects women in their 30s and 40s who may simultaneously use combined oral contraceptives (COCs), progestin-only pills, hormonal IUDs, patches, or vaginal rings.

A 2021 cross-sectional analysis of U.S. insurance claims found that approximately 4.2% of women initiating anti-resorptive or anabolic bone agents were under age 50 and concurrently filling a hormonal contraceptive prescription [2]. The question of safety between these two drug classes is clinically relevant even if the overlap population is small. Rheumatologists, endocrinologists, and primary care providers need clear guidance on whether concurrent use requires any modification.

Romosozumab Pharmacokinetics: No CYP Involvement

Romosozumab is a humanized IgG2 monoclonal antibody. Its clearance follows the same proteolytic catabolism pathway as endogenous immunoglobulins [1]. The drug is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4) or P-glycoprotein transporters.

This matters enormously. Hormonal contraceptives depend on CYP3A4 for ethinyl estradiol hydroxylation and on CYP3A4/CYP2C19 for progestin metabolism [3]. A drug that interferes with these enzymes can reduce contraceptive efficacy (enzyme induction) or increase hormone exposure (enzyme inhibition). Romosozumab does neither.

The FDA-approved prescribing information for Evenity states: "No formal drug interaction studies have been conducted with romosozumab" but notes the antibody's clearance mechanism makes pharmacokinetic interactions "unlikely" [1]. This is consistent with the class-wide behavior of therapeutic monoclonal antibodies. A 2020 systematic review in Clinical Pharmacology & Therapeutics examining 47 monoclonal antibodies found zero confirmed CYP-mediated drug-drug interactions among those that do not modulate cytokines involved in CYP regulation [4].

Hormonal Contraceptive Pharmacology and Potential Overlap Points

Combined hormonal contraceptives contain a synthetic estrogen (typically ethinyl estradiol 20-35 mcg) plus a progestin. Progestin-only methods include the minipill (norethindrone), hormonal IUDs (levonorgestrel), the implant (etonogestrel), and the injection (medroxyprogesterone acetate).

From a pharmacodynamic standpoint, estrogen and progesterone both influence bone metabolism. Estrogen suppresses osteoclast activity and reduces bone resorption [5]. Progestins may have minor anabolic effects on osteoblasts, though clinical significance remains debated. Romosozumab works by binding sclerostin, which increases osteoblast-mediated bone formation while simultaneously reducing bone resorption [1].

Could the bone-protective effects of hormonal contraceptives interact pharmacodynamically with romosozumab's mechanism? Theoretically, both promote bone accrual through different pathways. The combination might produce additive bone density gains rather than interference. The FRAME trial (N=7,180) and ARCH trial (N=4,093) did not stratify results by concurrent hormonal contraceptive use, but subgroup analyses by age showed consistent efficacy across premenopausal participants in the glucocorticoid-induced osteoporosis extension studies [6][7].

Cardiovascular Risk: The Shared Warning

The more clinically relevant concern is not a pharmacokinetic interaction but a shared safety signal. Romosozumab carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death [1]. In the ARCH trial, major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab-treated patients versus 1.9% on alendronate over 12 months [7].

Combined hormonal contraceptives independently increase venous thromboembolism (VTE) risk 3- to 4-fold and arterial thrombotic event risk approximately 1.6-fold, particularly in women over 35 who smoke [8]. The WHO Medical Eligibility Criteria classify COC use in women with multiple cardiovascular risk factors as Category 3/4 (unacceptable health risk) [9].

No study has examined whether concurrent romosozumab and COC use produces additive cardiovascular risk. The mechanisms differ: romosozumab's cardiovascular signal may relate to sclerostin's role in vascular calcification, while estrogen-progestin combinations affect coagulation factor synthesis. Still, a prudent clinician should assess baseline cardiovascular risk before co-prescribing.

For patients with pre-existing cardiovascular disease or multiple risk factors, the Endocrine Society's 2022 guidelines recommend choosing denosumab or teriparatide over romosozumab regardless of contraceptive status [10]. If romosozumab is selected, progestin-only contraceptive methods (which carry lower VTE risk) may represent a safer concurrent choice than COCs in higher-risk individuals.

Clinical Monitoring When Using Both Drugs

No specific laboratory monitoring is mandated for this drug combination. Standard monitoring for each drug individually applies:

For romosozumab: serum calcium before each monthly dose (hypocalcemia is a known adverse effect), blood pressure assessment, and awareness of cardiovascular symptoms [1]. Correct hypocalcemia and ensure adequate calcium (1,000-1 to 200 mg/day) and vitamin D (800-1 to 000 IU/day) intake before initiation.

For hormonal contraceptives: blood pressure measurement before prescribing and at follow-up visits, lipid panel for patients with cardiovascular risk factors, and screening for contraindications per CDC or WHO eligibility criteria [9].

The overlap monitoring that clinicians should consider: obtain a baseline lipid panel and repeat at 6 months if the patient has any cardiovascular risk factor (age over 35, smoking history, BMI over 30, family history of premature CVD, hypertension). Document a clear cardiovascular risk assessment before initiating romosozumab in any patient on combined hormonal contraception.

Contraceptive Efficacy Is Not Affected

This point deserves direct emphasis. Romosozumab will not cause contraceptive failure. The mechanisms that reduce hormonal contraceptive efficacy are well-characterized: CYP3A4 induction (rifampin, certain anticonvulsants, St. John's Wort), P-glycoprotein induction, or gastrointestinal absorption interference [3]. Romosozumab is administered subcutaneously, cleared by proteolysis, and has no effect on hepatic enzyme activity.

Patients can be reassured that their birth control will work exactly as expected while receiving Evenity injections. No backup contraception is needed. No timing separation between doses is required.

Premenopausal Osteoporosis: When This Combination Applies

The typical romosozumab candidate is a postmenopausal woman over 55 with a T-score at or below -2.5 and high fracture risk. Premenopausal use is off-label but occurs in specific scenarios:

Glucocorticoid-induced osteoporosis remains the most common reason. Women with systemic lupus erythematosus, inflammatory bowel disease, or severe asthma taking prednisone 7.5 mg/day or more for three months or longer develop significant bone loss [11]. The American College of Rheumatology's 2022 guidelines recommend anabolic agents (teriparatide or romosozumab) for patients at very high fracture risk regardless of menopausal status [12].

Osteogenesis imperfecta in adults represents another, rarer scenario. A phase 2 trial (NCT04895358) is evaluating romosozumab in adults with osteogenesis imperfecta, many of whom are premenopausal women using contraception.

In both situations, the treating physician should document that hormonal contraceptive use does not represent a contraindication and proceed with standard romosozumab dosing: 210 mg subcutaneously (split as two 105 mg injections) once monthly for 12 months [1].

Transition Planning After 12 Months of Romosozumab

Romosozumab's FDA label limits treatment to 12 monthly doses. Bone density gained during treatment is lost rapidly without sequential anti-resorptive therapy [6]. The standard approach is transitioning to denosumab or a bisphosphonate after the romosozumab course.

For patients on hormonal contraceptives, denosumab (Prolia) presents no interaction concerns for the same pharmacokinetic reasons as romosozumab: it is a monoclonal antibody cleared by proteolytic catabolism [13]. Bisphosphonates (alendronate, zoledronic acid) are also free of CYP interactions and do not affect contraceptive efficacy.

The clinical takeaway: the entire osteoporosis treatment sequence (romosozumab followed by denosumab or bisphosphonate) can proceed without modification to a patient's hormonal contraceptive regimen.

Special Populations: Depot Medroxyprogesterone Acetate (DMPA) Users

DMPA (Depo-Provera) deserves separate mention. Long-term DMPA use is associated with reduced bone mineral density (BMD), approximately 5-6% loss at the lumbar spine over 5 years, due to estrogen suppression [14]. The FDA added a black box warning to DMPA in 2004 regarding bone loss.

A patient who develops clinically significant bone loss from DMPA and requires romosozumab presents no pharmacokinetic interaction concern. The pharmacodynamic question is more nuanced: romosozumab builds bone while DMPA contributes to bone loss through estrogen suppression. Prescribing romosozumab while continuing DMPA may partially counteract the treatment's benefit.

The clinical decision should weigh contraceptive alternatives. If the patient can switch to a method without bone density effects (copper IUD, levonorgestrel IUD where systemic absorption is minimal, or barrier methods), this optimizes romosozumab's efficacy. If DMPA is the patient's preferred or only viable option, concurrent use is not contraindicated, and romosozumab's anabolic potency (approximately 13% lumbar spine BMD gain in FRAME) likely outweighs DMPA's catabolic effect [6].

Summary of Evidence and Clinical Recommendation

The interaction between romosozumab and hormonal contraceptives is pharmacokinetically nil. No dose adjustment, timing separation, backup contraception, or additional laboratory monitoring beyond standard-of-care is required. The one area of clinical judgment involves cardiovascular risk stacking in patients using combined estrogen-progestin contraceptives who also carry baseline risk factors, where progestin-only alternatives may be preferable.

Prescribers documenting a patient's medication list before initiating romosozumab should note hormonal contraceptive use, confirm the absence of cardiovascular contraindications to either drug independently, and proceed with treatment per the standard 12-dose protocol at 210 mg monthly [1][10].